search
Back to results

How to Reduce Suicidal Thoughts and Impulsivity in Depression (DEPIMPULSE)

Primary Purpose

Unipolar Depression, Impulsive Behavior, Suicidal Ideation

Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
active tDCS stimulating left DLPFC
active tDCS stimulating right OFC
sham tDCS
Sponsored by
Centre Hospitalier Universitaire de Besancon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Unipolar Depression focused on measuring transcranial stimulation, tDCS, left PreFrontalDorsoLateral Cortex, right OrbitoFrontal Cortex

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Man or woman older than 18 years oldRight-handed Signed Informed Consent form Subject affiliated to or beneficiary from a French social security regime Inpatient or outpatient at the Adult Psychiatry Service Diagnosis of Major Depressive Disorder according to the 5th edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria and confirmation by the MINI Structured Clinical Interview MADRS score ≥ 18 Beck Scale for Suicide Ideation (BSS) score ≥8 Under antidepressant treatment Absence of severe progressive neurologic and/or somatic pathologies (specially tumors, degenerative diseases) Exclusion Criteria: tDCS contraindication Younger than 18 years old Left-handed under mood stabilizer and/or antiepileptic treated by ECT or rTMS or tDCS for the current eposide Subject under measure of protection or guardianship of justice Presence of other psychiatric pahtologies Subject beneficiary from a legal protection regime Subject unlikely to cooperate or low cooperation stated by investigator Subject not covered by social security Pregnant woman Subject being in the exclusion period of another study or provided for by the "National Volunteer File"

Sites / Locations

  • CHU de Besançon
  • CHU de Clermont-Ferrand
  • Hôpital Chenevier, GH Henri Mondor
  • CHU de Montpellier

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Sham Comparator

Arm Label

active tDCS on left DLPFC

active tDCS on right OFC

sham tDCS

Arm Description

Active tDCS applied on left dorsolateral prefrontal cortex [DLPFC]

Active tDCS applied on right orbitofrontal cortex [OFC]

Sham tDCS applied on left dorsolateral prefrontal cortex [DLPFC]

Outcomes

Primary Outcome Measures

BSS scores
Difference of Beck's Scale for Suicide Ideation [BSS] score between Day 0 and Day 5, and between the arm active tDCS on left DLPFC and the arm active tDCS on right COF. This scale contains 19 items to assess the risk level for suicide among general population. French version of this scale is designed for autovaluation. Each item is quoted from 0 (no suicidal thoughts) to 2 (high degrees of suicidal intent).

Secondary Outcome Measures

BSS scores
Difference of Beck's Scale for Suicide Ideation [BSS] score between Day 0 and Day 5, +W2 and +W4 between the 3 arms This scale contains 19 items to assess the risk level for suicide among general population. French version of this scale is designed for autovaluation. Each item is quoted from 0 (no suicidal thoughts) to 2 (high degrees of suicidal intent).
C-SSRS scores
Compared scores from the Columbia-Suicide Severity Rating Scale (C-SSRS). The C-SSRS is a clinician-rated tool that evaluates suicidal ideation and behavior. It is composed by 6 "yes/no" questions. High suicide risk is indicated when "yes" is answered to questions 4, 5 or 6.
BIS-10 scores
Compared scores from the French version of the Barratt Impulsiveness Scale (BIS-10). The French version of the BIS-10 is a self-rated 34 item questionnaire, composed by three subscales: motor-impulsivity, cognitive-impulsivity and non-planning-impulsivity. Each item is scored on a 0 to 4 points scale. Higher scores indicate higher levels of impulsivity.
UPPS scores
Compared scores from the Urgency, Premeditation (lack of), Perseverance (lack of), Sensation Seeking, Positive Urgency Impulsive Behavior Scale (UPPS-P). The French version of the UPPS-P is a self-rated 45 item scale, evaluating the following components: urgency, lack of premeditation, lack of perseverance and sensation seeking. Each item is scored on a base of 4 points. Higher scores indicate higher levels of impulsivity.
BART scores
Balloon Analogue Risk Task (BART), assessing risk-taking behavior
Cognitive assessment
Compared results from the experimental TEA, assessing cognitive functions.
Delay discounting with MCQ scores
Compared scores from the French version of the Monetary Choice Questionnaire (MCQ). The MCQ is a self-rated 27 item questionnaire which assessed the discounting. Delay discounting is the decline in the present value of a reward with delay to its receipt. Example item: " Would you prefer 25€ today or 75€ in 15 days? " For each item, subjects must choose between a low immediate reward and a higher delayed reward. Waiting times vary from 7 days to 186 days, and rewards are divided into 3 magnitudes: low (25-35€), medium (50-60€), high (75-85€). This will allow assessing: the influence of the the magnitude of the difference between the two rewards proposed, the impact of the time on the reward's subjective value (speed at which the reward is devalued over time), reflected in the k index. This index is calculated separately for each magnitude, and an average index is calculated for each subject. The more the k index is high, the more the subject is considered impulsive.
Severity of depressive symptoms evaluated by the clinician
Score achieved on the validated clinician questionnaire Quick Inventory of Depressive Symptomatology (QIDS-C16) evaluating the severity of depressive symptoms. The QIDS-C16 was derived from specified items in the IDS-C30, clinician-rated scale to assess the severity of a participant's depressive symptoms. Total scores range from 0-27, with a score of 0 indicating no depression and a score of 27 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression.
Severity of depressive symptoms evaluated by the patient
Score achieved on the validated self-reported (QIDS-SR16) evaluating the severity of depressive symptoms. QIDS-SR-16 is a standard questionnaire "The Quick Inventory of Depressive Symptomatology" (16-Item) (Self-Report). This covers questions on falling asleep, sleep during the night, waking up , sleeping too much, feeling sad ,appetite, weight, concentration , how they view themselves, thoughts of death and suicide, general interests, energy levels, feeling slowed down , feeling restless.
Quality of life measured with the EQ-5D-5L
Quality of life measured with the EQ-5D-5L
Psychological and Physical Pain-Visual Analogic Scale (PPP-VAS)
Likert scales from 0 (none) to 10 (maximum possible pain)

Full Information

First Posted
May 30, 2023
Last Updated
May 30, 2023
Sponsor
Centre Hospitalier Universitaire de Besancon
Collaborators
Fondation FondaMental
search

1. Study Identification

Unique Protocol Identification Number
NCT05894980
Brief Title
How to Reduce Suicidal Thoughts and Impulsivity in Depression
Acronym
DEPIMPULSE
Official Title
Controlled Randomized Non-comparative Trial Assessing Active Transcranial Direct Current Stimulation [tDCS] on Left Dorsoleteral Prefrontal Cortex Versus Active tDCS Active on Right Orbitofrontal Cortex to Treat Unipolar Depression
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
July 2023 (Anticipated)
Primary Completion Date
June 2025 (Anticipated)
Study Completion Date
February 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Besancon
Collaborators
Fondation FondaMental

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study aims at investigating if tDCS applied to left DLPFC or to right OFC to treatment as usual is effective in reducing severe suicidal ideas in major depressive episode.
Detailed Description
Depressive disorders are one of the most frequent pathologies in psychiatry. The lifetime prevalence of the characterized depressive episode is indeed particularly high, between 16.6% in the United States and 24.1% in France. Because of this high prevalence, and because they constitute a pathology with a high risk of suicidal behavior (SC), depressive disorders are a major target of medical strategies for suicide prevention. In addition to suicidal ideation, impulsivity, considered as the tendency to express spontaneous, excessive and/or unplanned behaviors, is recognized as being a major factor precipitating SCs. With a pilot, prospective, multicenter design, the perspectives of DEPIMPULSE include being able to develop an innovative therapeutic approach in the reduction of risky behaviors, in particular suicidal ideation, associated impulsivity, suicidal risk in patients suffering from depression, while improving our understanding of the behavioral aspects and associated cognitions. The treatment will be delivered during 5 consecutive days (D1 to D5). Baseline measures (D0) will be compared to those obtained after the treatment administration (last day of treatment (D5) and 2 weeks (+W2) and 1 month (+W4) after the end of treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Unipolar Depression, Impulsive Behavior, Suicidal Ideation
Keywords
transcranial stimulation, tDCS, left PreFrontalDorsoLateral Cortex, right OrbitoFrontal Cortex

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
active tDCS on left DLPFC
Arm Type
Experimental
Arm Description
Active tDCS applied on left dorsolateral prefrontal cortex [DLPFC]
Arm Title
active tDCS on right OFC
Arm Type
Active Comparator
Arm Description
Active tDCS applied on right orbitofrontal cortex [OFC]
Arm Title
sham tDCS
Arm Type
Sham Comparator
Arm Description
Sham tDCS applied on left dorsolateral prefrontal cortex [DLPFC]
Intervention Type
Device
Intervention Name(s)
active tDCS stimulating left DLPFC
Other Intervention Name(s)
Starstim® (Neuroelectrics, Spain)
Intervention Description
20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the left DLPFC
Intervention Type
Device
Intervention Name(s)
active tDCS stimulating right OFC
Other Intervention Name(s)
Starstim® (Neuroelectrics, Spain)
Intervention Description
20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the right OFC
Intervention Type
Device
Intervention Name(s)
sham tDCS
Other Intervention Name(s)
Starstim® (Neuroelectrics, Spain)
Intervention Description
20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 0 mA) applied to the left DLPFC
Primary Outcome Measure Information:
Title
BSS scores
Description
Difference of Beck's Scale for Suicide Ideation [BSS] score between Day 0 and Day 5, and between the arm active tDCS on left DLPFC and the arm active tDCS on right COF. This scale contains 19 items to assess the risk level for suicide among general population. French version of this scale is designed for autovaluation. Each item is quoted from 0 (no suicidal thoughts) to 2 (high degrees of suicidal intent).
Time Frame
Baseline (Day 0), Day 5 (D5)
Secondary Outcome Measure Information:
Title
BSS scores
Description
Difference of Beck's Scale for Suicide Ideation [BSS] score between Day 0 and Day 5, +W2 and +W4 between the 3 arms This scale contains 19 items to assess the risk level for suicide among general population. French version of this scale is designed for autovaluation. Each item is quoted from 0 (no suicidal thoughts) to 2 (high degrees of suicidal intent).
Time Frame
Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Title
C-SSRS scores
Description
Compared scores from the Columbia-Suicide Severity Rating Scale (C-SSRS). The C-SSRS is a clinician-rated tool that evaluates suicidal ideation and behavior. It is composed by 6 "yes/no" questions. High suicide risk is indicated when "yes" is answered to questions 4, 5 or 6.
Time Frame
Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Title
BIS-10 scores
Description
Compared scores from the French version of the Barratt Impulsiveness Scale (BIS-10). The French version of the BIS-10 is a self-rated 34 item questionnaire, composed by three subscales: motor-impulsivity, cognitive-impulsivity and non-planning-impulsivity. Each item is scored on a 0 to 4 points scale. Higher scores indicate higher levels of impulsivity.
Time Frame
Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Title
UPPS scores
Description
Compared scores from the Urgency, Premeditation (lack of), Perseverance (lack of), Sensation Seeking, Positive Urgency Impulsive Behavior Scale (UPPS-P). The French version of the UPPS-P is a self-rated 45 item scale, evaluating the following components: urgency, lack of premeditation, lack of perseverance and sensation seeking. Each item is scored on a base of 4 points. Higher scores indicate higher levels of impulsivity.
Time Frame
Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Title
BART scores
Description
Balloon Analogue Risk Task (BART), assessing risk-taking behavior
Time Frame
Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Title
Cognitive assessment
Description
Compared results from the experimental TEA, assessing cognitive functions.
Time Frame
Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Title
Delay discounting with MCQ scores
Description
Compared scores from the French version of the Monetary Choice Questionnaire (MCQ). The MCQ is a self-rated 27 item questionnaire which assessed the discounting. Delay discounting is the decline in the present value of a reward with delay to its receipt. Example item: " Would you prefer 25€ today or 75€ in 15 days? " For each item, subjects must choose between a low immediate reward and a higher delayed reward. Waiting times vary from 7 days to 186 days, and rewards are divided into 3 magnitudes: low (25-35€), medium (50-60€), high (75-85€). This will allow assessing: the influence of the the magnitude of the difference between the two rewards proposed, the impact of the time on the reward's subjective value (speed at which the reward is devalued over time), reflected in the k index. This index is calculated separately for each magnitude, and an average index is calculated for each subject. The more the k index is high, the more the subject is considered impulsive.
Time Frame
Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Title
Severity of depressive symptoms evaluated by the clinician
Description
Score achieved on the validated clinician questionnaire Quick Inventory of Depressive Symptomatology (QIDS-C16) evaluating the severity of depressive symptoms. The QIDS-C16 was derived from specified items in the IDS-C30, clinician-rated scale to assess the severity of a participant's depressive symptoms. Total scores range from 0-27, with a score of 0 indicating no depression and a score of 27 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression.
Time Frame
Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Title
Severity of depressive symptoms evaluated by the patient
Description
Score achieved on the validated self-reported (QIDS-SR16) evaluating the severity of depressive symptoms. QIDS-SR-16 is a standard questionnaire "The Quick Inventory of Depressive Symptomatology" (16-Item) (Self-Report). This covers questions on falling asleep, sleep during the night, waking up , sleeping too much, feeling sad ,appetite, weight, concentration , how they view themselves, thoughts of death and suicide, general interests, energy levels, feeling slowed down , feeling restless.
Time Frame
Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Title
Quality of life measured with the EQ-5D-5L
Description
Quality of life measured with the EQ-5D-5L
Time Frame
Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Title
Psychological and Physical Pain-Visual Analogic Scale (PPP-VAS)
Description
Likert scales from 0 (none) to 10 (maximum possible pain)
Time Frame
Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Man or woman older than 18 years oldRight-handed Signed Informed Consent form Subject affiliated to or beneficiary from a French social security regime Inpatient or outpatient at the Adult Psychiatry Service Diagnosis of Major Depressive Disorder according to the 5th edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria and confirmation by the MINI Structured Clinical Interview MADRS score ≥ 18 Beck Scale for Suicide Ideation (BSS) score ≥8 Under antidepressant treatment Absence of severe progressive neurologic and/or somatic pathologies (specially tumors, degenerative diseases) Exclusion Criteria: tDCS contraindication Younger than 18 years old Left-handed under mood stabilizer and/or antiepileptic treated by ECT or rTMS or tDCS for the current eposide Subject under measure of protection or guardianship of justice Presence of other psychiatric pahtologies Subject beneficiary from a legal protection regime Subject unlikely to cooperate or low cooperation stated by investigator Subject not covered by social security Pregnant woman Subject being in the exclusion period of another study or provided for by the "National Volunteer File"
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Djamila BENNABI, MD PhD
Phone
+33381219007
Email
dbennabi@chu-besancon.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Magali NICOLIER, PhD
Phone
+33381219007
Email
mnicolier@chu-besancon.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Djamila BENNABI, MD PhD
Organizational Affiliation
CHU de Besançon
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de Besançon
City
Besançon
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Djamila BENNABI, MD PhD
Facility Name
CHU de Clermont-Ferrand
City
Clermont-Ferrand
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pierre-Michel LLORCA, MD PhD
Facility Name
Hôpital Chenevier, GH Henri Mondor
City
Créteil
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mathilde ROSER, MD
Facility Name
CHU de Montpellier
City
Montpellier
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Philippe COURTET, MD PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

How to Reduce Suicidal Thoughts and Impulsivity in Depression

We'll reach out to this number within 24 hrs